nj neuro
for the patient for the healthcare provider research post grad physician referal about us

logos

CORTICAL - BASAL GANGLIONIC DEGENERATION (CBGD)
Philip A. Hanna, MD
Parkinson's Disease and Movement Disorders Center
New Jersey Neuroscience Institute
Edison, New Jersey

What is Cortical-Basal Ganglionic Degeneration?

Cortical-basal ganglionic degeneration (or corticobasal degeneration) (CBGD) is an atypical parkinsonism (parkinsonism plus) syndrome of unknown cause. CBGD results in gradual loss of function of the cortex and basal ganglia, usually predominantly on one side of the brain. The most striking feature is the gradual loss of use (typically learned functions) of one hand or leg ("apraxia"). Patients may experience painful stiffness of limbs and muscle spasms, typically affecting one side of the body more than the other. Other symptoms include a coarse tremor or jerking movement (myoclonus) of limbs. Sensation may be affected on one or both sides of the body. In up to 50% of patients, a limb may be perceive by the patient as being foreign and/or having a "mind of its own", and make seemingly purposeful movements which are beyond the patient's control ("alien" limb). 
Similar to other atypical parkinsonian syndromes, treatment with levodopa and related medications is rarely, if ever, helpful. Muscle spasms and myoclonus may be reduced with tranquilizers, or with botulinum toxin injections.

Articles For Further Reading:

Hanna PA, Doody RS. Alien Limb Syndrome. In: Goetz CG, Lang AE, Litvan I, eds. Corticobasal Degeneration: Clinical and Research Aspects. Advances in Neurology Series. Lippincott-Raven Publishers, 1999. (In press).

Kumar R, Bergeron C, Pollanen MS, Lang AE. Cortical-basal ganglionic degeneration. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders. Baltimore:Williams and Wilkins, 1998:297-316.

Kompoliti K, Goetz CG, Boeve BF, et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 1998;55:957-961.

Jankovic J. Treatment of parkinsonian syndromes. In: Kurlan R, ed. The Treatment of Movement Disorders. J.B. Lippincott Company, Philadelphia, 1995:95-114.